Trials / Completed
CompletedNCT02063659
Telotristat Etiprate for Carcinoid Syndrome Therapy
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telotristat etiprate | Telotristat etiprate tablets |
| DRUG | Placebo | Placebo-matching telotristat etiprate tablets |
Timeline
- Start date
- 2014-03-11
- Primary completion
- 2016-03-29
- Completion
- 2016-03-29
- First posted
- 2014-02-14
- Last updated
- 2018-02-26
- Results posted
- 2017-09-25
Locations
50 sites across 11 countries: United States, Australia, Belgium, Canada, France, Germany, Israel, Netherlands, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02063659. Inclusion in this directory is not an endorsement.